Find information about updates, cancellations and how Inova is taking the appropriate steps to protect the safety of our caregivers, patients, team members and the community.
Lung cancer the is the second most common cancer in both men and women – and the leading cause of cancer death in the U.S. Thanks to smoking cessation and advances in early detection and treatment, lung cancer deaths are declining.
Annual lung cancer screening with low-dose computed tomography (LDCT) is recommended for adults ages 55 to 80 who have a 30 pack-year smoking history and currently smoke, or have quit within the past 15 years. Inova’s Lung Cancer Screening program is designed to detect cancer in its earliest, most treatable stage. Should cancer be detected, a multidisciplinary team of board certified interventional pulmonologists, thoracic surgeons and thoracic medical and radiation oncologists work hand-in-hand to coordinate and manage the patient’s care.
Join Dr. Amit “Bobby” Mahajan, board-certified interventional pulmonologist and Medical Director of the Inova Interventional Pulmonology and Complex Airway Disease Program, and Dr. Michael Weyant, board-certified thoracic surgeon and Medical Director of the Inova Thoracic Surgery Program, for an interactive discussion about the evolution of lung cancer screening and the cutting-edge technology, research and treatment options available today.
Thursday, November 4, 2021
6 - 7:30 p.m.
Zoom Meeting information will be sent in confirmation email.